IL17A and neoplasm: While this population only represents a minor portion of the tumor infiltrating lymphocytes, scRNA-Seq on syngeneic 4T1 tumors revealed that IL-17A is uniquely expressed and secreted from these specialized T cells into the TME yet numerous cell types in the TME can bind this cytokine by expressing its receptor (IL-17ra) underlying the potential impact of IL-17A in the TME (SFigure 2).